Business Context and Reporting Period
Alnylam Pharmaceuticals, Inc. filed a Form 8-K on November 14, 2017, reporting events occurring on November 13, 2017. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. It focuses exclusively on the terms of a capital raise.
- Shares Offered: 5,600,000 shares of common stock.
- Offering Price: $125.00 per share to the public.
- Price to Company: $121.875 per share (after underwriting discounts).
- Expected Net Proceeds: Approximately $682.1 million (excluding the over-allotment option).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 840,000 additional shares.
Material Changes
The primary material change is the execution of an underwriting agreement with Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC. This transaction represents a significant increase in the company's equity capital and cash liquidity upon closing.
Outlook, Risks, and Management Commentary
The offering is expected to close on November 16, 2017, subject to customary closing conditions. The shares are being issued pursuant to a shelf registration statement filed on May 5, 2017. The filing does not provide specific management commentary on future operational guidance or new risk factors beyond the standard conditions of the offering.
Investor Verification Checklist
- Verify the final closing date of the offering (expected November 16, 2017).
- Confirm whether the underwriters exercise the option to purchase the additional 840,000 shares.
- Review the attached press release (Exhibit 99.1) for specific details on the intended use of proceeds.
- Check subsequent filings for the actual net proceeds received after final expense adjustments.